Abstract
Candida infections are a source of significant mortality and morbidity in the neonatal intensive care unit. Treatment strategies continue to change as additional antifungals become available and studies in neonates are performed. Amphotericin B deoxycholate has been favored for many years, but fluconazole has the most data supporting its use in neonatal Candida infections and is often employed for prophylaxis as well as treatment. Voriconazole and posaconazole have limited utility in the nursery and are rarely used. The echinocandins are increasingly administered for invasive Candida infections, although higher doses are required in neonates than in older children and adults.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Amphotericin B / pharmacokinetics
-
Amphotericin B / therapeutic use
-
Antifungal Agents / pharmacokinetics
-
Antifungal Agents / therapeutic use*
-
Candidiasis / drug therapy*
-
Deoxycholic Acid / pharmacokinetics
-
Deoxycholic Acid / therapeutic use
-
Dose-Response Relationship, Drug
-
Drug Combinations
-
Echinocandins / pharmacokinetics
-
Echinocandins / therapeutic use
-
Fluconazole / therapeutic use
-
Humans
-
Infant, Newborn
-
Infant, Newborn, Diseases / drug therapy*
-
Infant, Newborn, Diseases / microbiology
-
Intensive Care Units, Neonatal
-
Neonatology / methods*
-
Neonatology / trends
-
Pyrimidines / pharmacokinetics
-
Pyrimidines / therapeutic use
-
Triazoles / pharmacokinetics
-
Triazoles / therapeutic use
-
Voriconazole
Substances
-
Antifungal Agents
-
Drug Combinations
-
Echinocandins
-
Pyrimidines
-
Triazoles
-
Deoxycholic Acid
-
posaconazole
-
Amphotericin B
-
amphotericin B, deoxycholate drug combination
-
Fluconazole
-
Voriconazole